Cooley advised Jiangsu Hengrui Pharmaceuticals on the deal. Jiangsu Hengrui Pharmaceuticals (“Hengrui”), a global pharmaceutical company focused on scientific and technological innovation, signed a global license agreement...
You must be a Standard 1 Year member to access this content.
Cooley advised Jiangsu Hengrui Pharmaceuticals on the deal. Jiangsu Hengrui Pharmaceuticals (“Hengrui”), a global pharmaceutical company focused on scientific and technological innovation, announced its strategic collaboration...
You must be a Standard 1 Year member to access this content.
Cooley advised Turning Point Therapeutics, while Kirkland & Ellis advised Bristol Myers Squibb on the deal. Bristol Myers Squibb (NYSE:BMY), a global biopharmaceutical company, announced its...
You must be a Standard 1 Year member to access this content.
Cooley LLP advised Shoreline Biosciences on the deal. Shoreline Biosciences, a biotechnology company developing immunotherapies for cancer and other serious diseases, announced its worldwide strategic collaboration with...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented the underwriters in the offering. Longboard Pharmaceuticals, Inc. closed its initial public offering of 5 million shares of its common stock at...
You must be a Standard 1 Year member to access this content.
